Development and validation of a self-updating gout register from electronic health records data.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 16 01 2024
accepted: 10 04 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 25 4 2024
Statut: epublish

Résumé

To develop an automatic gout register from electronic health records (EHRs) data. We analysed the EHR of all patients >18 years old from a tertiary academic hospital (2013-2022) based on six criteria: International Classification of Diseases 10 gout diagnosis, urate-lowering therapy prescription, monosodium urate crystals in joint aspiration and gout-related terms in problem lists, clinical or imaging reports. We assessed the positive and negative predictive value (PPV and NPV) of the query by chart reviews. Of 2 110 902 outpatients and inpatients, 10 289 had at least one criterion for gout. The combination of joint aspiration OR diagnostic in the problem list OR≥2 other criteria created a register of 5138 patients, with a PPV of 92.4% (95% CI 88.5% to 95.0%) and an NPV of 94.3% (95% CI 91.9% to 96.0%). PPV and NPV were similar among outpatients and inpatients. Incidence was 2.9 per 1000 person-year and dropped by 30% from the COVID-19 pandemic onward. Patients with gout were on average 71.2 years old (SD 14.9), mainly male (76.5%), overweight (69.5%) and polymorbid (mean number of comorbidities of 3, IQR 1-5). More than half (57.4%) had received a urate-lowering treatment, 6.7% had a gout that led to a hospitalisation or ≥2 flares within a year and 32.9% received a rheumatology consultation. An automatic EHR-based gout register is feasible, valid and could be used to evaluate and improve gout management. Interestingly, the register uncovered a marked underdiagnosis or under-reporting of gout since the COVID-19 pandemic.

Identifiants

pubmed: 38663884
pii: rmdopen-2024-004120
doi: 10.1136/rmdopen-2024-004120
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Nils Bürgisser (N)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland nils.burgisser@hug.ch.
Division of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva Faculty of Medicine, Geneva, Switzerland.

Denis Mongin (D)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva Faculty of Medicine, Geneva, Switzerland.

Samia Mehouachi (S)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
Quality of Care Division, Geneva University Hospitals, Geneva, Switzerland.

Clement P Buclin (CP)

Division of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva Faculty of Medicine, Geneva, Switzerland.

Romain Guemara (R)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.

Pauline Darbellay Farhoumand (P)

Division of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.

Olivia Braillard (O)

Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.

Kim Lauper (K)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
Geneva Center for Inflammation research, University of Geneva Faculty of Medicine, Geneva, Switzerland.

Delphine S Courvoisier (DS)

Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva Faculty of Medicine, Geneva, Switzerland.
Quality of Care Division, Geneva University Hospitals, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH